obesityZealand taps Generate’s AI discovery engine in $1.2B obesity dealZealand Pharma will pay Generate Biomedicines $30 million (€27 million) upfront to discover protein drugs for obesity and other metabolic diseases, broadening its pipeline beyond peptides and small … more ➔
Meanwhile in biotechLundbeck starts Phase 2; Rewind secures funding; Beactica picks a degraderBeyond the main headlines, European biotech kept moving this week. Lundbeck and Neurosterix advanced neurological drug programs, Rewind secured funding for myelin repair, and Beactica selected a cancer … more ➔
startupUndecimal raises $18M to take siRNA beyond the liverUndecimal Bio has launched with $18 million (about €16 million) in seed funding to develop delivery molecules that carry gene-silencing medicines beyond the liver, initially targeting kidney and vascular … more ➔
obesityRoche’s China shopping spree continues with $1B Rona obesity pactRoche has licensed worldwide rights to Rona Therapeutics’ experimental ALK7-targeting RNA interference therapy for obesity and metabolic diseases, offering up to $100 million (about €89 million) … more ➔
licensingEnodia lands $500M Pfizer deal to target proteins at the point of synthesisParis-based Enodia Therapeutics is entering a partnership with big pharma Pfizer to discover and develop small molecules for targeted protein degradation at the point of synthesis with a deal that could … more ➔
clinical dataElicera’s CAR-T clears detectable lymphoma in eight patientsSwedish biotech Elicera Therapeutics reported complete metabolic responses in eight of 12 patients treated with its experimental CAR-T therapy ELC-301 in the Phase 1 portion of its CARMA trial. Six remained … more ➔
startupDesentum secures €28M for faster allergy immunotherapyFinnish biotech Desentum has raised €28 million in an oversubscribed equity round to advance three allergy immunotherapy programs, with Phase 2 results for its lead birch pollen candidate expected … more ➔
autoimmune diseaseWhat’s next for argenx, Europe’s autoimmune breakthrough?Over the past few years, Belgium’s argenx has become a biotech force to be reckoned with, driven by the success of its autoimmune drug Vyvgart (efgartigimod alfa) in diseases such as generalised … more ➔
SchizophreniaNewron plans heart tests to lift schizophrenia trial holdItaly’s Newron Pharmaceuticals has disclosed that the FDA kept U.S. enrollment in a Phase 3 trial of its schizophrenia drug evenamide on hold, citing five deaths across all the drug’s clinical studies. … more ➔
AppointmentsAlligator’s CFO takes the top job, Sensorion names finance chief and RQ Bio appoints new CMOEvery Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell us about the companies they join. This week: a CEO transition shaped by a strategic … more ➔
